Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFEPIME IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFEPIME IN PLASTIC CONTAINER.
ANCEF IN PLASTIC CONTAINER vs CEFEPIME IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic